Zura Bio Ltd（ZURA）股票分析ZURAZura Bio Ltd

Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Zura Bio Ltd is currently not a strong buy due to its high volatility and negative earnings, but it has potential upside based on analyst targets. The current price is $3.88, significantly below the analyst price target of $20, indicating a potential upside of over 400%. However, the stock has an RSI of 34.276, suggesting it is oversold, and a forward P/E ratio of 0, indicating uncertainty about future profitability. The main risk is the company's ongoing losses, with a net income loss of $26.3 million reported in Q2 2026, which raises concerns about its financial health.